Drug Discovery & Development
Evotec Appoints Dr Ingrid Müller as Chief Operating Officer
Evotec has announced the appointment of Dr Ingrid Müller as Chief Operating Officer (COO). Dr Müller will be joining...
Renaissance Pharma secures FDA Fast Track Designation and IND clearance for Daretabart in high-risk neuroblastoma
The US Food and Drug Administration (FDA) has granted Fast Track Designation for Daretabart (hu1418K322A), a novel anti-GD2 monoclonal...
AbbVie’s Elahere succeeds in phase 2 platinum-sensitive ovarian cancer trial
AbbVie has announced that late-breaking results from the phase 2 IMGN853-0420 trial.
The study evaluated the potential efficacy and safety...
Cell line development market to reach $8.95 billion by 2031 with Gene & Cell Therapy manufacturing growing at 10.88%
According to Mordor Intelligence, the global cell line development market is projected to grow from USD 4.97 billion in 2025 to USD 5.48 billion in...
Global Drug Delivery and Formulation (DDF) Summit
18-20 May Berlin, Germany
The Global Drug Delivery and Formulation (DDF) Summit is Europe’s premier gathering for professionals at the forefront of...
Chemspec Europe reveals new details about 2026 conference programme
6–7 May 2026 Koln, Germany
Chemspec Europe has unveiled further details of its highly anticipated conference programme, offering attendees...
Oragenics doses first patient in phase 2a clinical trial of drug for mild traumatic brain injury
Oragenics, a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, has announced that the first patient...
Bracco invests in GMP manufacturing facility for cell therapy products
Bracco Imaging, a global pharmaceutical company that develops, manufactures, and markets innovative healthcare solutions, announced an upgrade of its...
Virica Biotech and Fujifilm Biosciences collaborate to develop production enhancers
Virica Biotech, a cell enhancer company specialising in Viral Sensitizers for viral vector manufacturing, has announced receipt of advisory...
Novartis agrees to acquire Excellergy, building on allergy leadership with next-generation anti-IgE innovation
Novartis has announced that it has entered into an agreement to acquire Excellergy, a private biotech company developing next-generation...
Evotec to receive around $100 Million as part of Tubulis acquisition
Evotec SE has announced that it is expected to receive approximately $100 million in upfront consideration upon closing of...
Halozyme announces global collaboration and licence agreement with Vertex Pharmaceuticals for Hypercon™ technology
Halozyme Therapeutics has announced its wholly-owned subsidiary, Halozyme Hypercon, entered into a global exclusive collaboration and license agreement with...
- Advertisement -
- Advertisement -
- Advertisement -
- Advertisement -
Popular
© 2026 Pharma Press Publishing.